At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 430 enrolled
Drug / intervention
etoricoxib (MK0663) 120 mg +2 moredrug
Likely dose
etoricoxib (MK0663) 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Tolerability of MK0663/Etoricoxib in the Treatment of Pain After Abdominal Hysterectomy
In Brief
A Phase 3 clinical trial evaluating etoricoxib (MK0663) 120 mg, Comparator: Placebo, and 1 other intervention for Acute Pain Following a Total Abdominal Hysterectomy. Completed, enrolled 430 participants.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedNov 2008
Primary CompletionJul 2010
TodayJul 2026
First PostedNov 11, 2008
Enrollment StartOct 1, 2008
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.6 years ago
Interventions
etoricoxib (MK0663) 120 mgdrug
120 mg of etoricoxib (MK0663) for a total of 5 days
Comparator: Placebodrug
Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
etoricoxib (MK0663) 90 mgdrug
90 mg of etoricoxib (MK0663) for a total of 5 days